In 71 children with IVIG-resistant MIS-C randomised to infliximab, methylprednisolone or anakinra, needing a second randomised drug was more likely with anakinra than infliximab (adjusted OR 3.42, 95% CI 1.03–12.29); steroids and infliximab were similar; no serious AEs.
RCTn = 73
Jain et al. Multisystem Inflammatory Syndrome Therapies in Children: A Comparative Effectiveness Trial